Abstract
Cholinesterase inhibition has gained attention in the treatment of some disease states, covering cholinergic deficiency. Alzheimer’s disease (AD) can be counted as the most important one among them. Indeed, the current drugs used in the treatment of AD are cholinesterase inhibitor molecules, besides memantine, and biological new drugs. Many pharmacophores have been suggested so far for cholinesterase inhibition and many of them possess a basic center with an amine function. Within this work, we have selected some simple amines and investigated their potential to inhibit acetylcholinesterase and butyrylcholinesterase enzymes. The results indicated that simple amines by themselves don’t have strong potential unless they are used with other pharmacophores.
References
- Blackard Jr, WG, Sood GK, Crowe DR and Fallon MB (1998). Tacrine: a cause of fatal hepatotoxicity?. J Clin Gastroenterol 26(1): 57-59.
- Gao H, Jiang Y, Zhan J and Sun Y (2021). Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer’s disease agents. Bioorg Chem 114: 105149.
- Gulcan HO and Orhan IE (2020). The main targets involved in neuroprotection for the treatment of Alzheimer’s disease and Parkinson disease. Curr Pharm Des 26(4): 509-516.
- Gulcan HO and Orhan IE (2021). Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds. Curr Med Chem 21(30): 2752-2765.
- Krall WJ, Sramek JJ and Cutler NR (1999). Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33(4): 441-450.
- Norouzbahari M, Burgaz EV, Ercetin T, Fallah A, Foroumadi A, et al. (2018). Design, synthesis and characterization of novel urolithin derivatives as cholinesterase inhibitor agents. Lett Drug Des Discov, 15(11): 1131-1140.
- Pagani M, Giuliani A, Oberg J, De Carli F, Morbelli S, et al. (2017). Progressive disintegration of brain networking from normal aging to Alzheimer disease: analysis of independent components of 18F-FDG PET data. J Nucl Med 58(7): 1132-1139.
Abstract
References
- Blackard Jr, WG, Sood GK, Crowe DR and Fallon MB (1998). Tacrine: a cause of fatal hepatotoxicity?. J Clin Gastroenterol 26(1): 57-59.
- Gao H, Jiang Y, Zhan J and Sun Y (2021). Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer’s disease agents. Bioorg Chem 114: 105149.
- Gulcan HO and Orhan IE (2020). The main targets involved in neuroprotection for the treatment of Alzheimer’s disease and Parkinson disease. Curr Pharm Des 26(4): 509-516.
- Gulcan HO and Orhan IE (2021). Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds. Curr Med Chem 21(30): 2752-2765.
- Krall WJ, Sramek JJ and Cutler NR (1999). Cholinesterase inhibitors: a therapeutic strategy for Alzheimer disease. Ann Pharmacother 33(4): 441-450.
- Norouzbahari M, Burgaz EV, Ercetin T, Fallah A, Foroumadi A, et al. (2018). Design, synthesis and characterization of novel urolithin derivatives as cholinesterase inhibitor agents. Lett Drug Des Discov, 15(11): 1131-1140.
- Pagani M, Giuliani A, Oberg J, De Carli F, Morbelli S, et al. (2017). Progressive disintegration of brain networking from normal aging to Alzheimer disease: analysis of independent components of 18F-FDG PET data. J Nucl Med 58(7): 1132-1139.
Details
| Primary Language | English |
|---|---|
| Subjects | Pharmaceutical Sciences |
| Journal Section | Research Articles |
| Authors | |
| Publication Date | July 22, 2024 |
| Submission Date | June 24, 2024 |
| Acceptance Date | July 9, 2024 |
| Published in Issue | Year 2024 Volume: 7 Issue: 1 |
